MedTrace Logo

Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients

NCT03084952 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2020-03-19

No results posted yet for this study

Summary

It is a randomized phase II clinical study, unicentre aimed to evaluate the tolerability, safety and efficacy of 18-Methoxyoronaridine as a candidate of tegumentary leishmaniasis treatment.

Conditions

  • Leishmaniasis; American, Cutaneous
  • Drug Side Effect

Interventions

DRUG

18-Methoxycoronaridine

Drug under evaluation for leishmaniasis treatment

DRUG

Glucantime

Leishmaniasis standard drug in Brazil

Sponsors & Collaborators

  • Infan Industria Quimica Farmaceutica Nacional

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-31
Primary Completion
2023-12-31
Completion
2024-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03084952 on ClinicalTrials.gov